NBI-827104 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epileptic Encephalopathy

Conditions

Epileptic Encephalopathy, Continuous Spike and Wave During Sleep

Trial Timeline

Apr 26, 2021 → Oct 11, 2022

NCT ID

NCT04625101

About NBI-827104 + Placebo

NBI-827104 + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Epileptic Encephalopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04625101. Target conditions include Epileptic Encephalopathy, Continuous Spike and Wave During Sleep.

What happened to similar drugs?

0 of 4 similar drugs in Epileptic Encephalopathy were approved

Approved (0) Terminated (0) Active (4)

🔄LorazepamPfizerPhase 3

🔄1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + PlaceboPraxis Precision MedicinesPhase 3

🔄1mg elsunersen + 0.5mg elsunersenPraxis Precision MedicinesPhase 3

🔄SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04625101	Phase 2	Completed	Apr 26, 2021	Oct 11, 2022	Epileptic Encephalopathy
NCT04880616	Phase 2	Completed	Apr 20, 2021	Jun 8, 2022	Essential Tremor

Competing Products

14 competing products in Epileptic Encephalopathy

See all competitors

Product	Company	Stage	Hype Score
Perampanel Oral Suspension + Perampanel Tablet	Eisai	Phase 2	42
Lorazepam	Pfizer	Phase 3	40
Lorazepam	Pfizer	Pre-clinical	26
levetiracetam (add-on)	UCB	Phase 2	31
ESES treated with clobazam	Lundbeck	Pre-clinical	23
NBI-921352 + Placebo	Neurocrine Biosciences	Phase 2	24
NBI-827104	Neurocrine Biosciences	Phase 2	24
NBI-921352	Neurocrine Biosciences	Phase 2	36
Epidiolex 100 mg/mL Oral Solution	Jazz Pharmaceuticals	Phase 1	26
1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo	Praxis Precision Medicines	Phase 3	44
1mg elsunersen + 0.5mg elsunersen	Praxis Precision Medicines	Phase 3	44
SAGE-547	Supernus Pharmaceuticals	Pre-clinical	20
SAGE-547	Supernus Pharmaceuticals	Phase 1/2	26
SAGE-547 + Placebo	Supernus Pharmaceuticals	Phase 3	34